IL217920A0 - 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nico tinamide and salts thereof as hdl cholesterol raising agents - Google Patents

5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nico tinamide and salts thereof as hdl cholesterol raising agents

Info

Publication number
IL217920A0
IL217920A0 IL217920A IL21792012A IL217920A0 IL 217920 A0 IL217920 A0 IL 217920A0 IL 217920 A IL217920 A IL 217920A IL 21792012 A IL21792012 A IL 21792012A IL 217920 A0 IL217920 A0 IL 217920A0
Authority
IL
Israel
Prior art keywords
trifluoro
dichloro
ethoxy
cyclohexyl
hydroxy
Prior art date
Application number
IL217920A
Other versions
IL217920A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL217920A0 publication Critical patent/IL217920A0/en
Publication of IL217920A publication Critical patent/IL217920A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL217920A 2009-09-11 2012-02-02 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6- (2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof IL217920A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (2)

Publication Number Publication Date
IL217920A0 true IL217920A0 (en) 2012-03-29
IL217920A IL217920A (en) 2015-11-30

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217920A IL217920A (en) 2009-09-11 2012-02-02 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6- (2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof

Country Status (35)

Country Link
US (1) US8227491B2 (en)
EP (1) EP2475645B1 (en)
JP (1) JP5604520B2 (en)
KR (1) KR101382871B1 (en)
CN (1) CN102639506B (en)
AR (2) AR078352A1 (en)
AU (1) AU2010294277B2 (en)
BR (1) BR112012005511B8 (en)
CA (1) CA2771493C (en)
CL (1) CL2012000611A1 (en)
CO (1) CO6491033A2 (en)
CR (1) CR20120089A (en)
CY (1) CY1114377T1 (en)
DK (1) DK2475645T3 (en)
EC (1) ECSP12011723A (en)
ES (1) ES2423821T3 (en)
HK (1) HK1172021A1 (en)
HR (1) HRP20130869T1 (en)
IL (1) IL217920A (en)
IN (1) IN2012DN00763A (en)
MA (1) MA33563B1 (en)
MX (1) MX2012002254A (en)
MY (1) MY161103A (en)
NZ (1) NZ597514A (en)
PE (1) PE20120863A1 (en)
PL (1) PL2475645T3 (en)
PT (1) PT2475645E (en)
RS (1) RS52987B (en)
RU (1) RU2541475C2 (en)
SG (1) SG179035A1 (en)
SI (1) SI2475645T1 (en)
TW (1) TWI412363B (en)
UA (1) UA107088C2 (en)
WO (1) WO2011029827A1 (en)
ZA (1) ZA201201599B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
CA2602787C (en) * 2005-04-06 2013-12-24 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
AU2007304365A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
AU2010294277B2 (en) 2015-07-09
AR078352A1 (en) 2011-11-02
MA33563B1 (en) 2012-09-01
RU2012113924A (en) 2013-10-20
CL2012000611A1 (en) 2012-09-07
MX2012002254A (en) 2012-03-16
US20110065759A1 (en) 2011-03-17
CN102639506B (en) 2014-09-03
IL217920A (en) 2015-11-30
EP2475645B1 (en) 2013-07-03
HRP20130869T1 (en) 2013-10-25
WO2011029827A1 (en) 2011-03-17
NZ597514A (en) 2013-10-25
HK1172021A1 (en) 2013-04-12
DK2475645T3 (en) 2013-07-22
JP2013504534A (en) 2013-02-07
EP2475645A1 (en) 2012-07-18
IN2012DN00763A (en) 2015-06-26
ES2423821T3 (en) 2013-09-24
PE20120863A1 (en) 2012-07-23
KR20120048040A (en) 2012-05-14
PL2475645T3 (en) 2013-12-31
BR112012005511B1 (en) 2021-03-02
MY161103A (en) 2017-04-14
JP5604520B2 (en) 2014-10-08
AR114032A2 (en) 2020-07-15
TW201114427A (en) 2011-05-01
AU2010294277A1 (en) 2012-02-09
RU2541475C2 (en) 2015-02-20
SI2475645T1 (en) 2013-10-30
CA2771493A1 (en) 2011-03-17
TWI412363B (en) 2013-10-21
UA107088C2 (en) 2014-11-25
ECSP12011723A (en) 2012-04-30
KR101382871B1 (en) 2014-04-08
CA2771493C (en) 2017-08-29
PT2475645E (en) 2013-08-05
CO6491033A2 (en) 2012-07-31
BR112012005511B8 (en) 2021-05-25
RS52987B (en) 2014-02-28
CR20120089A (en) 2012-03-22
ZA201201599B (en) 2012-11-28
CY1114377T1 (en) 2016-08-31
CN102639506A (en) 2012-08-15
SG179035A1 (en) 2012-04-27
BR112012005511A2 (en) 2016-04-19
US8227491B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
ZA201201599B (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nico tinamide and salts thereof as hdl cholesterol raising agents
HK1219306A1 (en) Methods and compositions for sleep disorders and other disorders
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
EP2360155A4 (en) 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity
IL197577A0 (en) 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
GB0805477D0 (en) Pyrimidines triazines and their use as pharmaceutical agents
ZA201004239B (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
EP2264017A4 (en) Heterocyclic derivative and use thereof
ZA200808191B (en) Pyridine and pyrimidine derivatives as MGLUR2 antagonists
PT2493306E (en) Synergistic herbicidal composition containing fluroxypyr and cyhalofop
HK1135983A1 (en) Multi-substituted pyridyl sulfoximines and their use as insecticides
IL217774A0 (en) Compositions for treating gaucher disease and uses thereof
HK1150555A1 (en) Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis 24-
EP1876178A4 (en) Cyanopyridine derivative and use thereof as medicine
PL2594248T3 (en) Active ingredient combination and use thereof
BRPI1015967A2 (en) "hinge unit, and piece of furniture."
EP2383263A4 (en) Novel thiazolidinedione derivative and use thereof
EP2268281A4 (en) Thienopyrroles and pyrrolothiazoles as new therapeutic agents
EP2284160A4 (en) Pyrimidine derivative having cell-protecting activity and use thereof
IL215483A0 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
HK1135987A1 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use 4--6-(222--1-)
EP2435470A4 (en) Muteins of the pyrroline-5-carboxylate reductase 1
EP2276501A4 (en) Methods and compositions for genetic and retinal disease
EP2190990A4 (en) Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease
GB0805664D0 (en) Pryimidines, triazines and thier use as pharmaceutical agents

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed